Status:
COMPLETED
Clinical Study of Lacrimal Drainage Obstruction Diseases Using Dacryoendoscopy
Lead Sponsor:
Tianjin Eye Hospital
Conditions:
Lacrimal Duct Obstruction
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Nasolacrimal duct obstruction (NLDO) can manifest as epiphora or recurrent infections with mucopurulent discharge and may even cause social embarrassment. Dacryoendoscopic-assisted laser dacryoplasty ...
Detailed Description
Lacrimal drainage obstruction can manifest as epiphora or recurrent infections with mucopurulent discharge and may even cause social embarrassment. Obstruction can occur at any level along the lacrima...
Eligibility Criteria
Inclusion
- (1) confirmed diagnosis of nasolacrimal duct obstruction or stenosis, based on dacryoendoscopic examination with or without radiologic confirmation on dacryocystogram; (2) recurrent or persistent and symptomatic epiphora; (3) follow-up of longer than 6 months after removal of the silicone stent.
Exclusion
- (1) congenital or traumatic lacrimal duct obstruction; (2) previous acute dacryocystitis; (3) facial nerve palsy; (4) lower eyelid or punctal malposition or laxity of sufficient severity to contribute to epiphora; (5) previous dacryocystorhinostomy; (6) incomplete medical records.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
522 Patients enrolled
Trial Details
Trial ID
NCT05999058
Start Date
November 1 2019
End Date
November 1 2023
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China, 300020